Tag: study

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global 3D Printed Drones Market size & share revenue was valued at approximately USD 710.5 Million in 2024 and is expected to reach USD 851.5 Million in 2025 and is expected to reach around USD 3,855.5 Million by 2034, at a CAGR of 20.7% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are The Boeing Company, AeroVironment Inc., BAE Systems plc, Draganfly Innovations Inc., Thales Group, Parrot Drones SAS, General Atomics, Skydio Inc., Airbus SE, Flyability SA, Dronamics Global Limited, Kratos Defense & Security Solutions Inc., Lockheed Martin Corporation, Firestorm Labs Inc., Northrop Grumman Systems Corporation and others.

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --

Charleston, SC, July 07, 2025 (GLOBE NEWSWIRE) -- TBA Outdoors has officially revealed its boldest evolution yet – rebranding as Untamed. This isn’t just a name change; it’s a declaration of intent. Fueled by grit and a mission to disrupt the status quo, Untamed enters the wild with a sharpened focus on integrated, results-obsessed strategies built to help outdoor brands thrive. In a landscape where competitors play it safe, Untamed slashes through mediocrity, introducing a fearless spirit, relentless momentum, and the creative firepower brands need to lead the pack.

PARIS, July 07, 2025 (GLOBE NEWSWIRE) --  PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been successfully dosed in its Phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead program, PST-611, in humans.